{"title":"揭示grp75介导的线粒体稳定性通过70 kDa热休克蛋白抑制剂的亚细胞锚定促进乳腺癌存活","authors":"Maojun Jiang, , , Yang Song, , , Hong Zhang, , , Fangkui Yin, , , Zhiyuan Hu, , , Zheming Wang, , , Yitong Li, , , Zihan Wang, , , Yanxin Zhang, , , Siyao Wang, , , Teng Yi, , , Ke Wang, , , Siting Feng, , , Zixuan Yang, , , Xiuwen Fan, , , Haoxin Lun, , , Ting Song, , , Ziqian Wang*, , and , Zhichao Zhang*, ","doi":"10.1021/acs.jmedchem.5c01279","DOIUrl":null,"url":null,"abstract":"<p >The 70 kDa heat shock protein (HSP70) isoforms play distinct roles in cancer, but their structural similarity limits isoform-specific inhibition. Here, we modified nonselective HSP70 inhibitor <b>S1g-10</b> via a subcellular anchoring strategy to generate compounds <b>5</b> and <b>8</b>, which selectively target mitochondrial-localized GRP75 and ER-localized GRP78, respectively. Both compounds modulated their intended targets in vivo. Additionally, GRP75, but not GRP78, was identified as a key regulator of mitochondrial membrane stability in breast cancer cells and maintains the stemness of breast cancer stem cells (BCSCs). Compared with normal cells, compound <b>5</b> exhibited selective toxicity against breast cancer cells and effectively suppressed the properties of BCSCs. This study provides novel chemical probes for studying specific isoforms of HSP70 and introduces a strategy to develop GRP75-targeted therapeutics for breast cancer.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 18","pages":"19169–19183"},"PeriodicalIF":6.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Revealing GRP75-Mediated Mitochondrial Stability That Promotes Breast Cancer Survival through Subcellular Anchoring of 70 kDa Heat Shock Protein Inhibitors\",\"authors\":\"Maojun Jiang, , , Yang Song, , , Hong Zhang, , , Fangkui Yin, , , Zhiyuan Hu, , , Zheming Wang, , , Yitong Li, , , Zihan Wang, , , Yanxin Zhang, , , Siyao Wang, , , Teng Yi, , , Ke Wang, , , Siting Feng, , , Zixuan Yang, , , Xiuwen Fan, , , Haoxin Lun, , , Ting Song, , , Ziqian Wang*, , and , Zhichao Zhang*, \",\"doi\":\"10.1021/acs.jmedchem.5c01279\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The 70 kDa heat shock protein (HSP70) isoforms play distinct roles in cancer, but their structural similarity limits isoform-specific inhibition. Here, we modified nonselective HSP70 inhibitor <b>S1g-10</b> via a subcellular anchoring strategy to generate compounds <b>5</b> and <b>8</b>, which selectively target mitochondrial-localized GRP75 and ER-localized GRP78, respectively. Both compounds modulated their intended targets in vivo. Additionally, GRP75, but not GRP78, was identified as a key regulator of mitochondrial membrane stability in breast cancer cells and maintains the stemness of breast cancer stem cells (BCSCs). Compared with normal cells, compound <b>5</b> exhibited selective toxicity against breast cancer cells and effectively suppressed the properties of BCSCs. This study provides novel chemical probes for studying specific isoforms of HSP70 and introduces a strategy to develop GRP75-targeted therapeutics for breast cancer.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 18\",\"pages\":\"19169–19183\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01279\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01279","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Revealing GRP75-Mediated Mitochondrial Stability That Promotes Breast Cancer Survival through Subcellular Anchoring of 70 kDa Heat Shock Protein Inhibitors
The 70 kDa heat shock protein (HSP70) isoforms play distinct roles in cancer, but their structural similarity limits isoform-specific inhibition. Here, we modified nonselective HSP70 inhibitor S1g-10 via a subcellular anchoring strategy to generate compounds 5 and 8, which selectively target mitochondrial-localized GRP75 and ER-localized GRP78, respectively. Both compounds modulated their intended targets in vivo. Additionally, GRP75, but not GRP78, was identified as a key regulator of mitochondrial membrane stability in breast cancer cells and maintains the stemness of breast cancer stem cells (BCSCs). Compared with normal cells, compound 5 exhibited selective toxicity against breast cancer cells and effectively suppressed the properties of BCSCs. This study provides novel chemical probes for studying specific isoforms of HSP70 and introduces a strategy to develop GRP75-targeted therapeutics for breast cancer.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.